Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Safety/Tolerability and Efficacy of Rivastigmine in Taiwanese Patients with Alzheimer's Disease: A Prospective Post-Marketing Surveillance Study
Clinical Drug Investigation, 10/14/09
Chiu PY et al. – Based on the results of this study, rivastigmine administered usually at a dose of 3–6 mg twice daily was found to be well tolerated. Although the rate of adverse events was high, the majority of these symptoms were mild in severity and short in duration. This study also demonstrated the efficacy of rivastigmine in at least stabilizing the symptoms of Alzheimer's disease.
Related Articles
Does Diabetes Speed Up Memory Loss In Alzheimers Disease?
ScienceDaily, 10/28/09
Relevance Score: 70%
High Blood Pressure Likely in Alzheimers Offspring
MedLinePlus, 11/04/09
Relevance Score: 69%
Protective Role For Copper In Alzheimers Disease
ScienceDaily, 10/14/09
Relevance Score: 68%
More Iowans fight Alzheimer's
Internet Source, 11/17/09
Relevance Score: 67%
Obesity and Alzheimer’s Disease: A Link Between Body Weight and Cognitive Function in Old Age
American Journal of Alzheimer's Disease and Other Dementias, 10/07/09
Relevance Score: 67%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid
Multiple Sclerosis, 12/11/09
Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/11/09
Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


